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Abstract
Summary Osteoporosis causes an elevated fracture risk. We
propose the continued use of T-scores as one means for
diagnosis but recommend that, alternatively, hip fracture;
osteopenia-associated vertebral, proximal humerus, pelvis, or
some wrist fractures; or FRAX scores with ≥3% (hip) or 20%
(major) 10-year fracture risk also confer an osteoporosis
diagnosis.
Introduction Osteoporosis is a common disorder of reduced
bone strength that predisposes to an increased risk for frac-
tures in older individuals. In the USA, the standard criterion
for the diagnosis of osteoporosis in postmenopausal women
and older men is a T-score of≤−2.5 at the lumbar spine, femur
neck, or total hip by bone mineral density testing.
Methods Under the direction of the National Bone Health
Alliance, 17 clinicians and clinical scientists were appointed
to a working group charged to determine the appropriate
expansion of the criteria by which osteoporosis can be
diagnosed.
Results The group recommends that postmenopausal women
and men aged 50 years should be diagnosed with osteoporosis
if they have a demonstrable elevated risk for future fractures.
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This includes having a T-score of less than or equal to −2.5 at
the spine or hip as one method for diagnosis but also permits a
diagnosis for individuals in this population who have experi-
enced a hip fracture with or without bone mineral density
(BMD) testing and for those who have osteopenia by BMD
who sustain a vertebral, proximal humeral, pelvic, or, in some
cases, distal forearm fracture. Finally, the term osteoporosis
should be used to diagnose individuals with an elevated
fracture risk based on the World Health Organization
Fracture Risk Algorithm, FRAX.
Conclusions As new ICD-10 codes become available, it is our
hope that this new understanding of what osteoporosis repre-
sents will allow for an appropriate diagnosis when older
individuals are recognized as being at an elevated risk for
fracture.
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Introduction
Osteoporosis has been characterized as a skeletal disorder of
reduced bone strength that leads to an increased risk for
fracture, typically in the setting of low trauma such as a fall
from standing height. In the USA today, the standard criterion
for defining and diagnosing osteoporosis and applying the
ICD-9 code 733.0 is the finding of a T-score of≤−2.5 at the
lumbar spine, femur neck, or total hip by bone mineral density
(BMD) testing [1]. As T-scores decrease, the relative risk for
fracture increases. This principle makes the T-score an effec-
tive means of identifying those individuals at increased frac-
ture risk and offers a cut point that allows for a diagnosis of
osteoporosis. However, it is clear that there are other ways to
identify individuals at high fracture risk, including the occur-
rence of one or more of several types of low-trauma fractures
or through the use of fracture risk algorithms such as FRAX. It
has been suggested that either of these ways of predicting an
increased fracture risk should also enable the use of the
diagnostic term osteoporosis [2]. It is the purpose of this paper
to make the case that we should formalize this concept and
encourage clinicians to use the term osteoporosis when they
identify an older patient with an elevated fracture risk deter-
mined by any one of these criteria.
Osteoporosis is a public health concern that is associated
with over two million fractures per year in the USA [3]. This
disease continues to be underdiagnosed, and its management
with a variety of treatments, including adequacy of calcium
and vitamin D, exercise to improve balance and prevent falls,
and pharmacologic therapy as indicated to lower fracture risk,
remains suboptimal [3]. The diagnosis of osteoporosis based
on a T-score of≤−2.5 is and should remain one important way
to identify an individual with an increased risk for fracture.
Bone density testing is recommended based on age and risk
factor status in both men and women by the Surgeon
General’s Report on bone health and osteoporosis as well as
other guidelines [3–6], but only a small proportion of older
men and women have a BMD test [7]. Many who do receive
the test may still not be recognized as having an elevated
fracture risk because their scores reflect “osteopenia,” which
in some instances does indicate a high risk based on elevated
age or prior fracture history or other validated risk factors.
Prior fracture affords the highest risk for future fracture [4], yet
an older patient with a hip fracture may not be diagnosed as
having osteoporosis unless the patient has a BMD test with a
T-score of≤−2.5, and the majority of hip fracture patients have
T-scores that are better than −2.5 [8]. An incident vertebral
fracture strongly predicts an increased risk of another vertebral
fracture as soon as within the next year [9]. Several other
fracture types also increase the risk of future fracture [10],
and about half of patients with a hip fracture have already had
a previous fracture [11], yet the term osteoporosis is not
formally applied unless the BMD T-score is≤−2.5. Most
fractures occur in people with low bone mass, not “T-score”
osteoporosis, because a greater number of people have
osteopenia than osteoporosis as defined by BMD [12,
13]. The failure to detect clinical osteoporosis when it is
present likely contributes to the current lack of awareness of
the consequences of this disease by both clinicians and
patients, impacts the reimbursement strategies of payers,
influences policy makers in the public health sector by
underestimating the number of those at elevated fracture
risk, and affects the design of clinical trials of new agents to
reduce fracture risk by both pharmaceutical companies and the
FDA.
In a position paper published in 2012 [2], a recommenda-
tion was made to formally expand the criteria for allowing a
diagnosis of osteoporosis to include the presence of certain
low-trauma fractures or the determination of an elevated frac-
ture risk using FRAX, without a T-score of −2.5 or lower. A
proposal was made to assemble a task force of representatives
from the academic and clinical societies that represent the
bone field and osteoporosis in particular in the USA, to debate
the issue and to reach consensus on the clinical characteristics
that would allow and support a clinical diagnosis of osteopo-
rosis in all older individuals who have an elevated risk for
fracture.
Working group composition and charge
Under the direction of the National Bone Health Alliance
(NBHA), a group of 17 clinicians and clinical scientists were
appointed to a Clinical Diagnosis of Osteoporosis Working
Group. Three of the members are the three US-based authors
of the 2012 position paper [2]; six individuals were appointed
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by the National Osteoporosis Foundation (NOF), and six were
appointed by the American Society for Bone and Mineral
Research (ASBMR). One additional member is the represen-
tative to the NBHA of the American Academy of Orthopedic
Surgeons, and the final member is the Centers for Disease
Control Liaison to the NBHA. The committee carried out its
work bymeeting initially at the 2012 ASBMR annual meeting
and, thereafter, through several teleconferences. There was no
financial support by any entity for the committee’s work, and
full financial disclosure of the members is provided in this
document.
The committee set a series of principles in place to be clear
about its purpose. First, the population for whom the clinical
osteoporosis diagnostic criteria are intended include (a) post-
menopausal women and (b) men over the age of 50 in the
USA. This population is the same as that included in the NOF
Clinician’s Guide [3]. Second, the purpose of expanding the
criteria for making a diagnosis is limited to that; no specific
treatment recommendations are being suggested as a part of
this effort. While the committee agreed that some form of
management would likely apply in all persons diagnosed as
having osteoporosis by these new criteria (including the use of
anti-osteoporosis prescription medication in many but not all
cases), the sole purpose of this committee’s deliberations is to
expand the criteria by which osteoporosis can be diagnosed.
Third, in this report, the terms osteopenia and low bone mass
are being used interchangeably and refer to a bone mineral
density T-score at the spine, femur neck, or total hip that is<
−1.0 and>−2.5. Finally, the fractures we are considering as
being diagnostic for osteoporosis are low-trauma or low-
energy fractures, such as those occurring in our population
from, as an example, a fall from standing height. Fractures
resulting from major trauma, e.g., automobile accidents or
falls off a roof, are not the fractures we are including in our
definition, though in this population, it is still recommended
that a bone density test be performed in such individuals to
determine if low bone mass or osteoporosis as defined by T-
score is present.
The committee recognized that making a diagnosis of a
condition is easiest when there are absolute criteria, such
as a blood test result above or below a certain cut point or
a biopsy of a lesion that has a clear pathological finding.
However, often in medicine, we make a diagnosis based on
clinical characteristics that reflect a syndrome that requires a
diagnosis in order to devise a treatment plan. A solid evidence
base coupled with physician judgment in some instances is
necessary, and a thoughtful clinician needs to consider wheth-
er or not certain clinical characteristics reflect an underlying
abnormality and to proceed with management accordingly.
Clearly, it is our intent to allow the diagnosis of oste-
oporosis to be made when there appears to be evidence
for believing that an elevated risk for fracture is present
but, equally, to afford the opportunity to not use the
term if it is not appropriate. Thus, in some instances where our
recommendations for making the diagnosis of osteoporosis
might apply in some cases but not in others, we have given
examples that may be helpful.
Committee recommendations
Fracture types that allow a diagnosis of osteoporosis
There was a consensus that for the population under consid-
eration, an individual who experiences a low-trauma hip
fracture can be diagnosed with osteoporosis, with or without
a BMD test. There was also a consensus that a low-trauma
clinical vertebral fracture, proximal humerus fracture, or pel-
vis fracture is diagnostic of osteoporosis in a person with
osteopenia. The incidental finding of a vertebral fracture on
a radiograph (a morphometric vertebral fracture) may also be
considered as diagnostic of osteoporosis if the clinician has a
reason to believe that it is likely to have been the result of low
bonemass and reduced bone strength. For example, if an older
woman has one or more vertebral deformities discovered on a
spine radiograph or through vertebral fracture assessment on a
DXA test and cannot recall whether or not she had an episode
of severe back pain but has BMD-based osteopenia, the oste-
oporosis diagnosis can be applied. However, if a 51-year-old
man has a chest radiograph that shows a vertebral compres-
sion deformity and the patient recalls a bad sports injury at the
age of 20 with weeks of severe back pain that gradually
resolved and a current BMD shows normal or minimally
low T-scores, the diagnosis of osteoporosis should not be
made.
Finally, in some instances, a low-trauma distal forearm
fracture in a person with osteopenia at the lumbar spine or
hip by BMD testing may be considered as diagnostic of
osteoporosis. A minority of the members of the working
group felt that in the population being considered, any wrist
fracture in the setting of osteopenia should be diagnosed as
osteoporosis. Their argument is that anyone over 50 years who
breaks a wrist regardless of the level of trauma and whose
assessment reveals low bone mass has osteoporosis, because
weaker bones are more likely to break than stronger bones,
and wrist fractures predict future fractures [10, 14]. However,
a majority of the working group felt that the circumstances of
the wrist fracture must be taken into account, and patient age
and the level of low bone mass be considered before labeling
the patient as having osteoporosis. For example, if a 50-year-
old woman crashes while roller blading sustaining a wrist
fracture and has normal or minimally low BMD when that
indicated test is performed (T-scores no lower than −1.3, as an
example), the diagnosis of osteoporosis is probably not ap-
propriate. However, if a 64-year-old individual with a T-score
of −2.2 slips on a curb, falls, and breaks her wrist, the
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diagnosis might apply, particularly if other risk factors
are present. In the case of wrist fracture, the diagnosis
may be made in some cases and not in others. Clinician
judgment, in the context of the clinician understanding
on the definition of osteoporosis, would need to be
applied, as often is the case in the real world of clinical
practice.
While many other fracture types increase the risk of future
fractures [10], the committee did not feel that all fracture
types, beyond those listed here, would necessarily constitute
a basis for an osteoporosis diagnosis. Therefore, at this time,
we suggest limiting the fracture types for an osteoporosis
diagnosis to the hip, spine, proximal humerus, pelvis, and, in
some cases, wrist, requiring a BMD test showing osteopenia
at the spine or hip in all cases except hip fracture. There was
also considerable discussion about the level of trauma that
led to the fracture, noting that the classical definition of
a “fragility” or “low-trauma” or “low-energy” fracture im-
plies, for example, a fall from standing height. Regardless of
the level of trauma, however, current recommendations call
for a measurement of BMD in older individuals who sustain a
fracture in order to rule in or out the possibility that low bone
mass was a contributing factor [3].
The role of FRAX in making the diagnosis of osteoporosis
FRAX is a World Health Organization-sponsored, country-
specific fracture risk assessment tool that combines BMD at
the femoral neck (or total hip) with a group of well-validated
and weighted clinical risk factors for fracture that are
largely independent of BMD [15]. It is based upon
epidemiological data from 60,000 women and men studied
prospectively to correlate risk factors for fracture with
fracture outcomes and then validated in independent
cohorts including more than 230,000 patients. It is
useful as a way of predicting the risk of hip fracture
and major osteoporotic fractures, i.e., clinical spine,
hip, proximal humerus, and distal forearm fractures, in
previously untreated men and women aged 40–90 years.
Its use in the USA allows the assessment of fracture risk in
both genders and four ethnic groups and is recommend-
ed primarily for individuals with a BMD finding of
osteopenia [3].
There was consensus that for the population under consid-
eration if the 10-year probability of hip fracture is ≥3 % or the
10-year probability of major osteoporotic fracture is ≥20 %, a
diagnosis of osteoporosis can be made. These two cut points
reflect treatment intervention thresholds in the USA as de-
scribed in the NOF Clinician’s Guide, based in the case of hip
fracture on cost-effectiveness criteria for hip fracture manage-
ment [16], and were viewed as a logical basis for making a
diagnosis of osteoporosis.
Further considerations
The committee believes that expanding the diagnostic criteria
for osteoporosis will assist in properly identifying a greater
number of people who are, in fact, at an elevated risk for
fracture, thus increasing awareness and encouraging strategies
to lower risk, which may or may not include prescription
therapy in all cases but would be recommended by current
guidelines for most [3]. The efficacy of many of the currently
available therapies to lower fracture risk is based upon clinical
trials in which entry criteria typically required BMD T-scores
of≤−2.5 at the spine or hip, not fracture history or FRAX
scores. In several studies, vertebral fractures were a part of the
entry criteria [17–19], with average T-scores reflecting
osteopenia in many cases, and in other cases, FRAX data
were applied post hoc to determine the efficacy based upon
baseline FRAX scores [20, 21]. Individual decisions regarding
treatment interventions with medications intended to lower
fracture risk will be necessary, and clinicians are advised to
consider whether there is evidence for a treatment effect for
each of the various therapies in the absence of a T-score
diagnosis of osteoporosis [2].
The committee also cautions that patients not be
overdiagnosed based upon these recommendations. We ac-
knowledge that fractures that occur with a high level of trauma
may or may not have been influenced by the level of bone
strength, and an evaluation, including BMD testing in most
cases, is needed after the fracture to help determine the role
that reduced bone strength may have played. Care should be
taken to avoid making a diagnosis of osteoporosis if the
fractures truly resulted from the severity of the trauma in the
presence of fairly normal bones. Conversely, a fracture in an
older individual after a fall from standing height is too often
blamed on the fall without due consideration of the strength of
the bones, and it is our hope that these new criteria will compel
a more thoughtful assessment of overall fracture risk, so that
underdiagnosis will also be reduced.
Conclusion
We recommend that postmenopausal women and also men
over the age of 50 years should be diagnosed as having
osteoporosis if it is demonstrated that the individual is at an
elevated risk for future fractures. We support the continued
use of BMD testing and the finding of a T-score of≤−2.5 at the
spine or hip as one way to make the diagnosis. We further
support the use of the term osteoporosis for individuals in this
population who have experienced a low-trauma hip fracture
and for those who have osteopenia by BMD who sustain a
low-trauma vertebral, proximal humerus, pelvis, or, in some
cases, distal forearm fracture. Hip, vertebral, distal radius, and
pelvis fractures constitute about two thirds of osteoporosis-
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associated fractures [22], and proximal humerus fractures are
among the four “major osteoporotic fractures” together with
hip, spine, and distal forearm fractures in FRAX [15]. Finally,
for individuals who have an elevated fracture risk based on
FRAX, the term osteoporosis can be used for diagnosis.
We hope to formalize these principles through future inter-
actions with third-party payers as well as with our colleagues
in primary care and orthopedics. As the new ICD-10 codes
become available in 2014–2015, it is our hope that this new
understanding on what osteoporosis represents will allow for
its appropriate diagnosis when older individuals are recog-
nized as being at an elevated risk for fracture.
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